Grass Pollen Allergy - Pipeline Review, H2 2016

 Table Of Content

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Grass Pollen Allergy Overview 6
Therapeutics Development 7
Pipeline Products for Grass Pollen Allergy - Overview 7
Grass Pollen Allergy - Therapeutics under Development by Companies 8
Grass Pollen Allergy - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Grass Pollen Allergy - Products under Development by Companies 11
Grass Pollen Allergy - Companies Involved in Therapeutics Development 12
ALK-Abello A/S 12
Allergy Therapeutics Plc 13
Biomay AG 14
Circassia Pharmaceuticals Plc 15
HAL Allergy BV 16
Roxall Medizin GmbH 17
Shionogi & Co., Ltd. 18
Grass Pollen Allergy - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
asapiprant - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
BM-32 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
clustoid wiesenlieschgras - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Pollinex Quattro Grass - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Grass Pollen Allergy - Dormant Projects 42
Grass Pollen Allergy - Product Development Milestones 43
Featured News & Press Releases 43
Jun 27, 2016: Allergy Therapeutics announces findings from mEEC dose range finding study G204 43
Jun 13, 2016: New Data From GAP Landmark Trial Confirm GRAZAX Prevents Asthma Symptoms in Children 43
May 25, 2016: Circassia Initiates Grass Allergy Immunotherapy Registration Study 45
Feb 18, 2016: Allergy Therapeutics Announces Patient enrolment completed in US Phase IIb study of GrassMATAMPL 46
Jan 28, 2016: Biomay initiates new phase II clinical trial with grass pollen allergy vaccine BM32 47
Jan 14, 2016: ALK announces top-line results from the five-year landmark GRAZAX Asthma Prevention trial in children 47
Jun 03, 2015: Positive phase IIb data on BM32, Biomay's innovative grass pollen allergy vaccine will be reported in hot topic session at major international scientific conference. 48
Jan 28, 2015: Biomay reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32 49
Apr 14, 2014: ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK 49
Feb 18, 2014: Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study 50
Feb 03, 2014: Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet) 51
Dec 16, 2013: Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32 51
Dec 12, 2013: FDA Advisory Committee meeting unanimously recommends approval of GRASTEK 51
Dec 10, 2013: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the grass sublingual AIT tablet 52
Nov 09, 2013: Merck's Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

List Of Tables

Number of Products under Development for Grass Pollen Allergy, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Grass Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2016 12
Grass Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H2 2016 13
Grass Pollen Allergy - Pipeline by Biomay AG, H2 2016 14
Grass Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2016 15
Grass Pollen Allergy - Pipeline by HAL Allergy BV, H2 2016 16
Grass Pollen Allergy - Pipeline by Roxall Medizin GmbH, H2 2016 17
Grass Pollen Allergy - Pipeline by Shionogi & Co., Ltd., H2 2016 18
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Grass Pollen Allergy - Dormant Projects, H2 2016 42 

To request a free sample copy of this report, please complete the form below.

Enter captcha code*

We never share your personal data. Privacy policy